[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 10 of about 18
1. Buglione M, De Bari B, Trevisan F, Ghirardelli P, Pedretti S, Triggiani L, Magrini SM: Role of external beam radiotherapy in the treatment of relapsing meningioma. Med Oncol; 2014 Mar;31(3):866
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of external beam radiotherapy in the treatment of relapsing meningioma.
  • The role of radiotherapy in the treatment of relapsing meningiomas is not well established.
  • Data of patients treated with radiotherapy for a relapsing meningioma were retrospectively analyzed.
  • From April 1986 to February 2011, 37 patients with a diagnosis of recurrent meningioma were treated.
  • Median age was 64 years (range 36-79).
  • A total of 18, 10, 5 and 4 patients were affected by relapsing benign, atypical, malignant meningiomas and meningiosarcomas, respectively (WHO classification).
  • OS at 1, 3, 5 and 8 years was 81, 55.6, 43.9 and 25.8%, respectively (median OS 45 months).
  • A statistical impact of the histology (WHO I vs. II, III and IV) on 5-year OS was also observed (OS 60 vs. 30%, 0 and 0%, p=0.010).
  • Conventional radiation therapy has an important role in multidisciplinary approach in the treatment of recurrence of meningiomas.
  • [MeSH-major] Meningeal Neoplasms / radiotherapy. Meningioma / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Radiotherapy
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Grading. Prognosis. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 2009 Jan;64(1):56-60; discussion 60 [19145156.001]
  • [Cites] J Clin Oncol. 1984 Oct;2(10):1139-43 [6491698.001]
  • [Cites] Curr Opin Oncol. 2012 Nov;24(6):666-71 [22759739.001]
  • [Cites] J Neurosurg. 1997 May;86(5):793-800 [9126894.001]
  • [Cites] Expert Rev Anticancer Ther. 2011 Nov;11(11):1749-58 [22050024.001]
  • [Cites] J Neurooncol. 1992 Jun;13(2):157-64 [1432033.001]
  • [Cites] Neurosurgery. 1987 Apr;20(4):525-8 [3587542.001]
  • [Cites] J Neurooncol. 2013 Dec;115(3):421-7 [24045968.001]
  • [Cites] J Neurooncol. 2013 May;113(1):135-41 [23443515.001]
  • [Cites] J Neurooncol. 2013 May;112(3):323-7 [23404622.001]
  • [Cites] J Neurooncol. 2013 Nov;115(2):241-7 [23949108.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] J Neurooncol. 2010 Sep;99(3):349-56 [20809249.001]
  • [Cites] J Neurooncol. 2013 Sep;114(2):219-27 [23737294.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1975 Mar;123(3):453-8 [1124827.001]
  • [Cites] J Neurooncol. 2000 May;48(1):51-5 [11026697.001]
  • [Cites] J Neurooncol. 2013 Sep;114(3):299-307 [23852621.001]
  • [Cites] J Neurooncol. 2005 Sep;74(2):157-65 [16193387.001]
  • [Cites] Acta Neurochir (Wien). 2013 Aug;155(8):1385-90; discussion 1390 [23728501.001]
  • [Cites] J Neurooncol. 1998 Apr;37(2):177-88 [9524097.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 1;46(1):57-61 [10656373.001]
  • [Cites] J Clin Neurosci. 2012 Sep;19(9):1261-4 [22784877.001]
  • [Cites] Oncology (Williston Park). 1995 Jan;9(1):83-91, 96; discussion 96, 99-101 [7718443.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Sep 1;39(2):427-36 [9308947.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1341-6 [7713792.001]
  • [Cites] Cancer. 2008 Oct 15;113(8):2146-51 [18756531.001]
  • [Cites] Radiother Oncol. 2001 Oct;61(1):65-70 [11578730.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Aug;15(2):299-304 [3403313.001]
  • [Cites] J Neurosurg. 1994 Feb;80(2):187-90 [8283254.001]
  • [Cites] Mayo Clin Proc. 1998 Oct;73(10):936-42 [9787740.001]
  • [Cites] Chin Med J (Engl). 2011 Aug;124(15):2387-91 [22029080.001]
  • [Cites] J Neurooncol. 2010 Sep;99(3):307-14 [20821343.001]
  • (PMID = 24504843.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Kwee LE, van Veelen-Vincent ML, Michiels EM, Kros JM, Dammers R: The importance of microsurgery in childhood meningioma: a case report. Childs Nerv Syst; 2015 Jan;31(1):161-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The importance of microsurgery in childhood meningioma: a case report.
  • INTRODUCTION: Although meningiomas are frequently diagnosed in adults, it is a rare (intracranial) tumor in the pediatric population, with an incidence of 0.06/100,000.
  • The pathology and treatment of meningiomas in adulthood has been a topic of increasing investigation.
  • So far, the treatment of pediatric meningiomas has been extrapolated from these results.
  • The question remains, however, whether translation of adult meningioma data into the childhood population is legitimate.
  • METHODS: We present the case of a 3-year-old girl diagnosed with an intraventricular malignant meningioma and type 2 neurofibromatosis.
  • Since, she has been stable with no neurological sequelae and/or recurrence of the meningioma.
  • CONCLUSION: Pediatric meningiomas are rare tumors and differ from their adult counterparts in various aspects.
  • We believe that gross total resection of meningioma in the pediatric population, when possible, is the treatment of choice.
  • [MeSH-major] Meningeal Neoplasms / surgery. Meningioma / surgery. Microsurgery / methods

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuro Oncol. 2013 Feb;15(2):224-34 [23223339.001]
  • [Cites] Expert Rev Neurother. 2012 Oct;12(10):1189-95; quiz 1196 [23082735.001]
  • [Cites] J Korean Neurosurg Soc. 2012 Dec;52(6):517-22 [23346322.001]
  • [Cites] Curr Opin Oncol. 2012 Nov;24(6):666-71 [22759739.001]
  • [Cites] Pediatr Neurosurg. 2005 Jan-Feb;41(1):1-7 [15886506.001]
  • [Cites] Childs Nerv Syst. 2013 Jan;29(1):83-7 [22972400.001]
  • [Cites] Childs Nerv Syst. 1989 Apr;5(2):83-6 [2736555.001]
  • [Cites] Childs Nerv Syst. 2009 Dec;25(12):1571-80 [19641924.001]
  • [Cites] Lancet Oncol. 2011 Dec;12(13):1229-39 [22094004.001]
  • [Cites] Clin Neurol Neurosurg. 2011 May;113(4):261-7 [21227570.001]
  • [Cites] Childs Nerv Syst. 2012 Jul;28(7):1009-15 [22543431.001]
  • [Cites] J Neurooncol. 2011 Aug;104(1):1-10 [21203895.001]
  • [Cites] Neurosurg Rev. 2006 Jan;29(1):36-40 [16220350.001]
  • [Cites] Pediatr Neurosurg. 2008;44(1):43-8 [18097190.001]
  • [Cites] Neurology. 2007 Sep 4;69(10):969-73 [17785665.001]
  • [Cites] Acta Neurochir (Wien). 2002 Dec;144(12):1265-70; discussion 1270 [12478337.001]
  • [Cites] J Neurosurg. 2005 Dec;103(6 Suppl):489-95 [16383246.001]
  • [Cites] Br J Neurosurg. 2008 Feb;22(1):13-25; discussion 24-5 [18224517.001]
  • [Cites] J Neurosurg Pediatr. 2010 Jun;5(6):615-21 [20515336.001]
  • [Cites] Childs Nerv Syst. 2012 Nov;28(11):1887-96 [22669518.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14719-24 [9405679.001]
  • [Cites] Cancer. 2008 Oct 15;113(8):2146-51 [18756531.001]
  • [Cites] Pediatr Neurosurg. 2012;48(1):30-4 [22922461.001]
  • [Cites] Childs Nerv Syst. 1996 Oct;12(10):582-8; discussion 589 [8934017.001]
  • [Cites] J Pediatr Neurosci. 2009 Jul;4(2):61-5 [21887184.001]
  • [Cites] Am J Med Genet. 1995 Mar 13;56(1):112-5 [7747773.001]
  • [Cites] Cancer Genet Cytogenet. 1991 Jun;53(2):271-7 [1676608.001]
  • (PMID = 25034239.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


3. Johnson MD, Shaw AK, O'Connell MJ, Sim FJ, Moses HL: Analysis of transforming growth factor β receptor expression and signaling in higher grade meningiomas. J Neurooncol; 2011 Jun;103(2):277-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of transforming growth factor β receptor expression and signaling in higher grade meningiomas.
  • Loss of TGF-βRs or its signaling components have been found in several human malignancies.
  • The expression and the role of TGF-βRs in regulating anaplastic meningioma growth has not been studied.
  • By western blot analysis, TGF-βRI was detected in the four fetal and adult leptomeninges, all 18 grade I, 14 grade II and six grade III meningiomas.
  • TGF-βRII was detected in none of the leptomeninges, 55% of grade I, 71% of grade II and weak to negative in five of six the grade III meningiomas analyzed.
  • Thus, only attenuated TGF-βRIII expression and TGFB growth inhibition may occur in select higher grade meningiomas.
  • Nonetheless, restoring TGF-β inhibition of meningioma cell proliferation may be an important objective in the design of new chemotherapies for these tumors.
  • [MeSH-major] Meningeal Neoplasms / metabolism. Meningioma / metabolism. Receptors, Transforming Growth Factor beta / biosynthesis. Signal Transduction / physiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Blotting, Western. Female. Humans. Male. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Endocrinol. 2009 Apr;23(4):539-48 [19164448.001]
  • [Cites] Br J Cancer. 2000 Mar;82(6):1171-6 [10735501.001]
  • [Cites] J Biol Chem. 1996 Jul 12;271(28):16567-72 [8663331.001]
  • [Cites] Int J Cancer. 1996 Oct 9;68(2):203-6 [8900429.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Feb;46(2):192-201 [17117417.001]
  • [Cites] Eur J Endocrinol. 2005 Feb;152(2):277-84 [15745937.001]
  • [Cites] J Biol Chem. 2000 Nov 24;275(47):36803-10 [10969078.001]
  • [Cites] Curr Top Dev Biol. 2005;71:1-52 [16344101.001]
  • [Cites] Carcinogenesis. 2008 Mar;29(3):528-35 [18174241.001]
  • [Cites] Cell. 2008 Jul 25;134(2):215-30 [18662538.001]
  • [Cites] Adv Cancer Res. 1998;74:49-139 [9561267.001]
  • [Cites] J Cancer Res Clin Oncol. 2008 Mar;134(3):345-51 [17680270.001]
  • [Cites] Cytokine Growth Factor Rev. 2000 Mar-Jun;11(1-2):23-35 [10708950.001]
  • [Cites] Breast Cancer Res. 2000;2(2):107-15 [11250700.001]
  • [Cites] Br J Cancer. 1999 Apr;80(1-2):194-205 [10389996.001]
  • [Cites] Crit Rev Eukaryot Gene Expr. 2007;17(4):281-93 [17725494.001]
  • [Cites] Trends Cell Biol. 1999 Jul;9(7):274-9 [10370243.001]
  • [Cites] Nature. 1996 Sep 12;383(6596):168-72 [8774881.001]
  • [Cites] J Neurosurg. 2010 May;112(5):934-9 [19698046.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Dec;64(12):1029-36 [16319713.001]
  • [Cites] Cancer Res. 1998 Nov 1;58(21):4805-10 [9809982.001]
  • [Cites] Oncogene. 2005 Aug 29;24(37):5742-50 [16123807.001]
  • [Cites] J Neurooncol. 2004 Jan;66(1-2):9-16 [15015765.001]
  • [Cites] Am J Pathol. 1992 Sep;141(3):633-42 [1325741.001]
  • [Cites] Science. 1998 May 15;280(5366):1086-8 [9582123.001]
  • [Cites] J Biol Chem. 1995 Dec 15;270(50):29628-31 [8530343.001]
  • [Cites] Exp Neurol. 1996 Dec;142(2):313-22 [8934562.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 1999 Sep;19(9):2127-32 [10479654.001]
  • [Cites] Gynecol Oncol. 2005 Feb;96(2):368-73 [15661223.001]
  • [Cites] Cell. 1992 Jun 26;69(7):1067-70 [1319842.001]
  • [Cites] Mutat Res. 2001 Aug 8;479(1-2):131-9 [11470488.001]
  • [Cites] Biochim Biophys Acta. 2009 Jul;1793(7):1165-73 [19339207.001]
  • [Cites] J Clin Invest. 2007 Jan;117(1):206-17 [17160136.001]
  • [Cites] Cancer Res. 1997 Feb 15;57(4):628-33 [9044838.001]
  • [Cites] J Cell Physiol. 2001 Jun;187(3):265-76 [11319750.001]
  • [Cites] Oncogene. 1991 Aug;6(8):1471-6 [1886718.001]
  • [Cites] Prostate. 2007 Feb 15;67(3):301-11 [17192875.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):183-202 [15674477.001]
  • [Cites] Nature. 1997 Oct 9;389(6651):631-5 [9335507.001]
  • [Cites] Oncogene. 2003 Sep 11;22(39):8053-62 [12970754.001]
  • [Cites] Int J Cancer. 1991 Aug 19;49(1):129-39 [1874566.001]
  • [Cites] Cytokine Growth Factor Rev. 2006 Feb-Apr;17(1-2):41-58 [16310402.001]
  • [Cites] Lab Invest. 1992 Sep;67(3):360-8 [1328762.001]
  • [Cites] J Endocrinol Invest. 2003 Jun;26(6):516-21 [12952364.001]
  • [Cites] Curr Top Dev Biol. 1990;24:219-59 [2199157.001]
  • [Cites] Cancer Res. 2007 Jun 1;67(11):5231-8 [17522389.001]
  • [Cites] Mol Cancer. 2007 Oct 15;6:64 [17937814.001]
  • [Cites] Adv Cancer Res. 2001;83:1-54 [11665716.001]
  • [Cites] J Biol Chem. 1994 May 6;269(18):13231-7 [8175753.001]
  • [Cites] J Neurooncol. 2009 Apr;92(2):129-36 [19034385.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1090-8 [17283142.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4679-82 [11406536.001]
  • [Cites] J Neuropathol Exp Neurol. 2009 Nov;68(11):1177-83 [19816200.001]
  • [Cites] J Biol Chem. 1999 Dec 24;274(52):37292-300 [10601295.001]
  • [Cites] Cancer Commun. 1989;1(2):117-25 [2561734.001]
  • [Cites] Prog Growth Factor Res. 1991;3(3):219-34 [1667366.001]
  • [Cites] Hum Mol Genet. 2007 Apr 15;16 Spec No 1:R14-20 [17613544.001]
  • [Cites] Lancet Neurol. 2006 Dec;5(12):1045-54 [17110285.001]
  • (PMID = 20853018.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Transforming Growth Factor beta
  •  go-up   go-down


Advertisement
4. Iwami K, Natsume A, Ohno M, Ikeda H, Mineno J, Nukaya I, Okamoto S, Fujiwara H, Yasukawa M, Shiku H, Wakabayashi T: Adoptive transfer of genetically modified Wilms' tumor 1-specific T cells in a novel malignant skull base meningioma model. Neuro Oncol; 2013 Jun;15(6):747-58
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adoptive transfer of genetically modified Wilms' tumor 1-specific T cells in a novel malignant skull base meningioma model.
  • BACKGROUND: Meningiomas are the most commonly diagnosed primary intracranial neoplasms.
  • Despite significant advances in modern therapies, the management of malignant meningioma and skull base meningioma remains a challenge.
  • Thus, the development of new treatment modalities is urgently needed for these difficult-to-treat meningiomas.
  • The goal of this study was to investigate the potential of build-in short interfering RNA-based Wilms' tumor protein (WT1)-targeted adoptive immunotherapy in a reproducible mouse model of malignant skull base meningioma that we recently established.
  • METHODS: We compared WT1 mRNA expression in human meningioma tissues and gliomas by quantitative real-time reverse-transcription polymerase chain reaction.
  • Human malignant meningioma cells (IOMM-Lee cells) were labeled with green fluorescent protein (GFP) and implanted at the skull base of immunodeficient mice by using the postglenoid foramen injection (PGFi) technique.
  • RESULTS: High levels of WT1 mRNA expression were observed in many meningioma tissues and all meningioma cell lines.
  • IOMM-Lee-GFP cells were successfully implanted using the PGFi technique, and malignant skull base meningiomas were induced in all mice.
  • The systemically delivered WT1-targeted PBMCs infiltrated skull base meningiomas and significantly delayed tumor growth and increased survival time.
  • CONCLUSIONS: We have established a reproducible mouse model of malignant skull base meningioma.
  • WT1-targeted adoptive immunotherapy appears to be a promising approach for the treatment of difficult-to-treat meningiomas.
  • [MeSH-major] Disease Models, Animal. Genetic Engineering. Immunotherapy, Adoptive. Meningeal Neoplasms / therapy. Meningioma / therapy. Skull Base Neoplasms / therapy. T-Lymphocytes / immunology. WT1 Proteins / metabolism
  • [MeSH-minor] Adoptive Transfer. Adult. Aged. Aged, 80 and over. Animals. Apoptosis. Blotting, Western. Cell Proliferation. Female. Flow Cytometry. Humans. Immunoenzyme Techniques. Leukocytes, Mononuclear / immunology. Leukocytes, Mononuclear / metabolism. Leukocytes, Mononuclear / pathology. Male. Mice. Mice, Inbred NOD. Mice, SCID. Middle Aged. RNA, Messenger / genetics. Real-Time Polymerase Chain Reaction. Reverse Transcriptase Polymerase Chain Reaction. T-Lymphocytes, Cytotoxic / immunology. T-Lymphocytes, Cytotoxic / pathology. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Meningioma.
  • Genetic Alliance. consumer health - Wilms' tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Immunol. 2008 Apr;20(2):211-20 [18502632.001]
  • [Cites] Hum Cell. 2004 Dec;17(4):211-7 [16035506.001]
  • [Cites] Neurosurgery. 2008 Jun;62(6 Suppl 3):1115-21; discussion 1121-3 [18695533.001]
  • [Cites] BMC Neurosci. 2008;9:83 [18778487.001]
  • [Cites] Clin Cancer Res. 2009 Sep 1;15(17):5323-37 [19723653.001]
  • [Cites] Cancer Res. 2009 Dec 1;69(23):9003-11 [19903853.001]
  • [Cites] Anticancer Res. 2009 Nov;29(11):4779-84 [20032435.001]
  • [Cites] J Neurosurg. 2010 May;112(5):913-9 [19645533.001]
  • [Cites] Expert Rev Vaccines. 2005 Aug;4(4):503-12 [16117707.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8878-86 [16951205.001]
  • [Cites] Blood. 2007 Jan 1;109(1):235-43 [16968899.001]
  • [Cites] Curr Opin Mol Ther. 2007 Feb;9(1):62-9 [17330403.001]
  • [Cites] Cancer Res. 2007 Apr 15;67(8):3898-903 [17440104.001]
  • [Cites] Mol Ther. 2007 Oct;15(10):1744-50 [17637721.001]
  • [Cites] J Immunol. 2007 Nov 1;179(9):5803-10 [17947653.001]
  • [Cites] Blood. 2007 Nov 15;110(10):3564-72 [17660381.001]
  • [Cites] J Neurosurg. 2008 Feb;108(2):304-10 [18240927.001]
  • [Cites] Brain Pathol. 2008 Apr;18(2):172-9 [18093250.001]
  • [Cites] J Neurooncol. 2010 Sep;99(3):433-43 [20730473.001]
  • [Cites] J Neurooncol. 2010 Sep;99(3):393-405 [20740303.001]
  • [Cites] Cancer Res. 2010 Nov 1;70(21):8426-34 [20861191.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2011 Apr;52(5):2532-9 [21071731.001]
  • [Cites] Blood. 2011 Aug 11;118(6):1495-503 [21673345.001]
  • [Cites] N Engl J Med. 2011 Aug 25;365(8):725-33 [21830940.001]
  • [Cites] J Neurosurg. 2012 Mar;116(3):630-5 [22149378.001]
  • [Cites] Acta Neurochir (Wien). 1998;140(10):1013-6; discussion 1016-7 [9856244.001]
  • [Cites] Blood. 2000 Jan 1;95(1):286-93 [10607714.001]
  • [Cites] J Neurosurg. 2000 Feb;92(2):306-14 [10659019.001]
  • [Cites] Clin Diagn Lab Immunol. 2001 Nov;8(6):1131-5 [11687452.001]
  • [Cites] Neurosurgery. 2001 Nov;49(5):1029-37; discussion 1037-8 [11846894.001]
  • [Cites] Neoplasia. 2002 Jul-Aug;4(4):304-11 [12082546.001]
  • [Cites] Clin Cancer Res. 2002 Aug;8(8):2626-31 [12171894.001]
  • [Cites] Trends Immunol. 2002 Sep;23(9):435-6; author reply 436-7 [12200063.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3175-82 [12384415.001]
  • [Cites] Surg Neurol. 2003 Oct;60(4):298-305; discussion 305 [14505844.001]
  • [Cites] Blood. 2003 Dec 1;102(12):3934-7 [12881303.001]
  • [Cites] Gene Ther. 2004 Apr;11(7):569-73 [15029226.001]
  • [Cites] Cancer. 1989 Dec 1;64(11):2243-9 [2804914.001]
  • [Cites] Neurosurgery. 1990 Sep;27(3):389-95; discussion 396 [2234331.001]
  • [Cites] J Neurosurg. 1995 Oct;83(4):596-9 [7545742.001]
  • [Cites] Science. 1996 Jul 5;273(5271):104-6 [8658175.001]
  • [Cites] J Neurosurg. 2005 Jan;102 Suppl:283-6 [15662826.001]
  • [Cites] Blood. 2005 Jul 15;106(2):470-6 [15790789.001]
  • [Cites] Surg Neurol. 2008 Sep;70(3):295-307; discussion 307 [18261772.001]
  • (PMID = 23460320.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / WT1 Proteins
  • [Other-IDs] NLM/ PMC3661093
  • [Keywords] NOTNLM ; Wilms' tumor 1 / adoptive immunotherapy / cranial nerve / skull base meningioma
  •  go-up   go-down


5. Kshettry VR, Ostrom QT, Kruchko C, Al-Mefty O, Barnett GH, Barnholtz-Sloan JS: Descriptive epidemiology of World Health Organization grades II and III intracranial meningiomas in the United States. Neuro Oncol; 2015 Aug;17(8):1166-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Descriptive epidemiology of World Health Organization grades II and III intracranial meningiomas in the United States.
  • BACKGROUND: Because World Health Organization (WHO) grades II and III meningiomas are relatively uncommon, there is limited literature on the descriptive epidemiology of these tumors, and the existing literature predates the 2000 WHO classification revisions.
  • Our purpose was to provide a modern, population-based study of the descriptive epidemiology of WHO II and III meningiomas in the United States.
  • METHODS: The Central Brain Tumor Registry of the United States (CBTRUS) was queried for intracranial meningiomas categorized by WHO grade for the 2004--2010 study period.
  • RESULTS: From 2004 to 2010, the incidence of WHO II intracranial meningiomas increased from 0.28 (95% CI, 0.27--0.29) to 0.30 (95% CI, 0.28-0.32), representing an APC of 3.6% (95%CI, 0.8%-6.5%).
  • Conversely, from 2000-2010, the incidence of WHO III meningiomas decreased from 0.13 (95% CI, 0.11-0.14) to 0.06 (95%CI, 0.06-0.07), representing an APC of -5.4% (95% CI, -6.8% to -4.0%).
  • From 2004 to 2010, the overall proportion of WHO I, II, and III intracranial meningiomas was 94.6%, 4.2%, and 1.2%, respectively.
  • For WHO II/III meningiomas, females in the 35-64 year age group had a higher incidence than males in the same age group, whereas males in the ≥ 75 year age group ≥ had a higher incidence.
  • Black and Asian Pacific Islander races were both associated with the highest incidence of WHO II/III meningiomas.
  • CONCLUSION: This study presents the most comprehensive evaluation of the modern descriptive epidemiology of WHO II and III meningiomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © The Author(s) 2015. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
  • [Cites] Neurosurgery. 1993 Dec;33(6):955-63 [8134008.001]
  • [Cites] Neuroepidemiology. 1993;12(5):270-9 [8309502.001]
  • [Cites] Cancer. 1999 May 1;85(9):2046-56 [10223247.001]
  • [Cites] J Neurooncol. 1999 Apr;42(2):109-16 [10421067.001]
  • [Cites] Neurosurgery. 2005 Sep;57(3):538-50; discussion 538-50 [16145534.001]
  • [Cites] Int J Cancer. 2005 Dec 20;117(6):996-1001 [15986431.001]
  • [Cites] Neurosurgery. 2005 Dec;57(6):1088-95; discussion 1088-95 [16331155.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Neurosurgery. 2007 Sep;61(3):495-503; discussion 503-4 [17881961.001]
  • [Cites] N Engl J Med. 2007 Nov 1;357(18):1821-8 [17978290.001]
  • [Cites] J Clin Oncol. 2008 Jan 10;26(2):279-82 [18182668.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2008 May;79(5):574-80 [17766430.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Aug 1;71(5):1388-93 [18294779.001]
  • [Cites] BMJ. 2009;339:b3016 [19687093.001]
  • [Cites] J Natl Cancer Inst. 2009 Dec 16;101(24):1721-4 [19959779.001]
  • [Cites] J Neurosurg. 2010 May;112(5):913-9 [19645533.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):1415-21 [20932661.001]
  • [Cites] Am J Epidemiol. 2012 Feb 15;175(4):309-14 [22287638.001]
  • [Cites] Int J Clin Exp Pathol. 2012;5(3):231-42 [22558478.001]
  • [Cites] J Registry Manag. 2013 Spring;40(1):32-5 [23778695.001]
  • [Cites] Neuro Oncol. 2013 Nov;15 Suppl 2:ii1-56 [24137015.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 1;46(1):57-61 [10656373.001]
  • [Cites] J Neurosurg. 1983 Jan;58(1):51-6 [6847909.001]
  • [Cites] J Neurosurg. 2004 Aug;101(2):210-8 [15309910.001]
  • [Cites] J Neurosurg. 2003 Nov;99(5):848-53 [14609164.001]
  • [Cites] Cancer. 1984 Oct 1;54(7):1435-8 [6467164.001]
  • [Cites] Aust N Z J Surg. 1984 Aug;54(4):331-6 [6593027.001]
  • [Cites] Surg Neurol. 1986 Mar;25(3):233-42 [3945904.001]
  • [Cites] J Neurosurg. 1989 Nov;71(5 Pt 1):665-72 [2809720.001]
  • [Cites] Neurosurgery. 1992 Jul;31(1):2-12 [1641106.001]
  • [Cites] J Natl Cancer Inst. 1992 Sep 2;84(17):1346-9 [1495104.001]
  • [Cites] Histopathology. 1993 Oct;23(4):349-53 [8300070.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1455-65 [9414189.001]
  • (PMID = 26008603.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NCCDPHP CDC HHS / DP / 5U58DP00381-03
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC4490879
  • [Keywords] NOTNLM ; anaplastic / atypical / epidemiology / malignant / meningioma
  •  go-up   go-down


6. Zhang D, Yu J, Guo Y, Zhao S, Shao G, Huang H: An intraventricular meningioma and recurrent astrocytoma collision tumor: a case report and literature review. World J Surg Oncol; 2015;13:37
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An intraventricular meningioma and recurrent astrocytoma collision tumor: a case report and literature review.
  • BACKGROUND: Intracranial meningioma and glioma collision tumors are relatively uncommon and are even more rarely located within the ventricles.
  • CASE PRESENTATION: Here, we report a case of a patient with an intraventricular meningioma and astrocytoma collision tumor.
  • A 39-year-old man previously underwent excision of an astrocytoma in the triangle area of the lateral ventricle and exhibited good post-surgery recovery.
  • The astrocytoma recurred in situ six years after the surgery, and the case was complicated by a malignant meningioma.
  • CONCLUSIONS: We conclude that a possible cause of the collision tumor formation between the intracranial meningioma and the astrocytoma was the recurrence of an astrocytoma-induced malignancy of the arachnoid cells in the choroid plexus.
  • [MeSH-major] Astrocytoma / complications. Brain Neoplasms / complications. Cerebral Ventricle Neoplasms / complications. Meningeal Neoplasms / complications. Meningioma / complications. Neoplasm Recurrence, Local / etiology
  • [MeSH-minor] Adult. Humans. Male. Prognosis

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathologe. 2004 Sep;25(5):402-5 [15164223.001]
  • [Cites] J Clin Neurosci. 2003 Mar;10(2):252-4 [12637065.001]
  • [Cites] J Neurosurg. 1981 Aug;55(2):282-6 [7252552.001]
  • [Cites] Neurosurgery. 1986 Jul;19(1):114-9 [3018623.001]
  • [Cites] Neurol Med Chir (Tokyo). 1987 Apr;27(4):325-8 [2446168.001]
  • [Cites] Surg Neurol. 1990 Feb;33(2):139-41 [2154868.001]
  • [Cites] Acta Neurochir (Wien). 1991;110(3-4):133-9 [1927605.001]
  • [Cites] Neurosurgery. 1995 Mar;36(3):599-604; discussion 604-5 [7753363.001]
  • [Cites] Ital J Neurol Sci. 1996 Aug;17(4):283-6 [8915759.001]
  • [Cites] Acta Neurochir (Wien). 1997;139(3):208-14 [9143586.001]
  • [Cites] Int J Epidemiol. 1998 Aug;27(4):579-86 [9758110.001]
  • [Cites] J Neurosurg. 1963 Nov;20:995-9 [14186102.001]
  • [Cites] Neurocirugia (Astur). 2005 Jun;16(3):266-70; discussion 270 [16007326.001]
  • [Cites] J Am Acad Dermatol. 2005 Nov;53(5 Suppl 1):S256-9 [16227103.001]
  • [Cites] Br J Neurosurg. 2005 Aug;19(4):368-75 [16455550.001]
  • [Cites] J Neurooncol. 2006 Mar;77(1):73-7 [16292489.001]
  • [Cites] Acta Neurochir (Wien). 2007 Jan;149(1):87-90; discussion 90 [17131066.001]
  • [Cites] Neurosurgery. 2007 Apr;60(4 Suppl 2):E401; discussion E401 [17415151.001]
  • [Cites] Neurol Neurochir Pol. 2007 May-Jun;41(3):272-5 [17629822.001]
  • [Cites] Zentralbl Neurochir. 2007 Aug;68(3):145-50 [17665342.001]
  • [Cites] Endocr Pathol. 2009 Spring;20(1):50-5 [19238590.001]
  • [Cites] Neurocirugia (Astur). 2009 Apr;20(2):176-8 [19554788.001]
  • [Cites] Neurol Neurochir Pol. 2009 Sep-Oct;43(5):479-83 [20054751.001]
  • [Cites] Neurol Neurochir Pol. 2010 Jan-Feb;44(1):102; author reply 103 [20419898.001]
  • [Cites] J Neurooncol. 2010 Aug;99(1):147-53 [20063176.001]
  • [Cites] J Cancer Res Ther. 2010 Apr-Jun;6(2):221-3 [20622373.001]
  • [Cites] Br J Neurosurg. 2010 Aug;24(4):471-3 [20726755.001]
  • [Cites] Br J Neurosurg. 2010 Dec;24(6):718-9 [20632878.001]
  • [Cites] J Neurooncol. 2012 Dec;110(3):397-402 [23076602.001]
  • [Cites] Lancet. 2000 Nov 4;356(9241):1576-7 [11075777.001]
  • [Cites] Br J Neurosurg. 2001 Feb;15(1):68-71 [11303668.001]
  • [Cites] Ann Diagn Pathol. 2002 Feb;6(1):44-8 [11842378.001]
  • [Cites] J Neurosurg. 1976 Oct;45(4):455-8 [956884.001]
  • (PMID = 25889820.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC4329203
  •  go-up   go-down


7. Ferraro DJ, Funk RK, Blackett JW, Ju MR, DeWees TA, Chicoine MR, Dowling JL, Rich KM, Drzymala RE, Zoberi I, Simpson JR, Jaboin JJ: A retrospective analysis of survival and prognostic factors after stereotactic radiosurgery for aggressive meningiomas. Radiat Oncol; 2014 Jan 27;9:38
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A retrospective analysis of survival and prognostic factors after stereotactic radiosurgery for aggressive meningiomas.
  • BACKGROUND: While most meningiomas are benign, aggressive meningiomas are associated with high levels of recurrence and mortality.
  • A single institution's Gamma Knife radiosurgical experience with atypical and malignant meningiomas is presented, stratified by the most recent WHO classification.
  • METHODS: Thirty-one patients with atypical and 4 patients with malignant meningiomas treated with Gamma Knife radiosurgery between July 2000 and July 2011 were retrospectively reviewed.
  • Overall survival was the primary endpoint and rate of disease recurrence in the brain was a secondary endpoint.
  • RESULTS: Post-Gamma Knife recurrence was identified in 11 patients (31.4%) with a median overall survival of 36 months and progression-free survival of 25.8 months.
  • Nine patients (25.7%) had died.
  • Three-year overall survival (OS) and progression-free survival (PFS) rates were 78.0% and 65.0%, respectively.
  • WHO grade II 3-year OS and PFS were 83.4% and 70.1%, while WHO grade III 3-year OS and PFS were 33.3% and 0%.
  • Recurrence rate was significantly higher in patients with a prior history of benign meningioma, nuclear atypia, high mitotic rate, spontaneous necrosis, and WHO grade III diagnosis on univariate analysis; only WHO grade III diagnosis was significant on multivariate analysis.
  • Overall survival was adversely affected in patients with WHO grade III diagnosis, prior history of benign meningioma, prior fractionated radiotherapy, larger tumor volume, and higher isocenter number on univariate analysis; WHO grade III diagnosis and larger treated tumor volume were significant on multivariate analysis.
  • CONCLUSION: Atypical and anaplastic meningiomas remain difficult tumors to treat.
  • WHO grade III diagnosis and treated tumor volume were significantly predictive of recurrence and survival on multivariate analysis in aggressive meningioma patients treated with radiosurgery.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuro Oncol. 2010 Jun;12(6):520-7 [20511189.001]
  • [Cites] J Neurooncol. 2009 Dec;95(3):367-75 [19562258.001]
  • [Cites] Expert Rev Neurother. 2011 Oct;11(10):1425-32 [21955199.001]
  • [Cites] Expert Rev Anticancer Ther. 2011 Nov;11(11):1749-58 [22050024.001]
  • [Cites] J Neurooncol. 2012 Mar;107(1):13-20 [22006176.001]
  • [Cites] J Neurooncol. 2012 May;108(1):179-85 [22359231.001]
  • [Cites] Stereotact Funct Neurosurg. 2012;90(5):316-24 [22797807.001]
  • [Cites] Acta Neurochir Suppl. 2013;116:85-9 [23417463.001]
  • [Cites] Acta Neurochir Suppl. 2013;116:91-7 [23417464.001]
  • [Cites] J Neurosurg. 2013 Aug;119(2):475-81 [23394332.001]
  • [Cites] Clin Neurol Neurosurg. 2010 Apr;112(3):177-82 [20056312.001]
  • [Cites] J Neurosurg. 2000 Dec;93 Suppl 3:62-7 [11143265.001]
  • [Cites] Neuro Oncol. 1999 Jan;1(1):14-25 [11554386.001]
  • [Cites] Neurosurgery. 2001 Nov;49(5):1029-37; discussion 1037-8 [11846894.001]
  • [Cites] Surg Neurol. 2003 Oct;60(4):298-305; discussion 305 [14505844.001]
  • [Cites] Lancet. 2004 May 8;363(9420):1535-43 [15135603.001]
  • [Cites] J Neurosurg. 2004 Jun;100(6):1002-13 [15200115.001]
  • [Cites] Cancer. 1993 Aug 1;72(3):639-48 [8334619.001]
  • [Cites] J Neurooncol. 1996 Sep;29(3):197-205 [8858525.001]
  • [Cites] J Neurosurg. 1997 May;86(5):793-800 [9126894.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1455-65 [9414189.001]
  • [Cites] Neurosurgery. 1998 Sep;43(3):405-13; discussion 413-4 [9733295.001]
  • [Cites] Cancer. 1999 May 1;85(9):2046-56 [10223247.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1515-9 [15590183.001]
  • [Cites] J Neurosurg. 2005 Jan;102 Suppl:283-6 [15662826.001]
  • [Cites] Strahlenther Onkol. 2006 Nov;182(11):641-6 [17072521.001]
  • [Cites] Virchows Arch. 2006 Nov;449(5):529-38 [17016718.001]
  • [Cites] Lancet Neurol. 2006 Dec;5(12):1045-54 [17110285.001]
  • [Cites] Neurosurgery. 2008 Jan;62(1):53-8; discussion 58-60 [18300891.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2008 May;79(5):574-80 [17766430.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Aug 1;71(5):1388-93 [18294779.001]
  • [Cites] J Neurooncol. 2010 Sep;99(3):379-91 [20809251.001]
  • (PMID = 24467972.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA91842
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3922849
  •  go-up   go-down


8. Garcia-Navarrete R, Garcia E, Arrieta O, Sotelo J: Hepatocyte growth factor in cerebrospinal fluid is associated with mortality and recurrence of glioblastoma, and could be of prognostic value. J Neurooncol; 2010 May;97(3):347-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocyte growth factor in cerebrospinal fluid is associated with mortality and recurrence of glioblastoma, and could be of prognostic value.
  • Malignant gliomas--glioblastoma multiforme and anaplastic astrocytoma--are among the most fatal forms of cancer in humans.
  • We measured the HGF content of cerebrospinal fluid (CSF) from patients with malignant glioma glioblastoma multiforme (WHO IV; n = 14), anaplastic astrocytoma (WHO III; n = 4), and meningioma (WHO I; n = 9), and from control subjects (n = 25), and found a high concentration of HGF in patients with malignant glioma.
  • However, CSF concentrations from glioblastoma multiforme and anaplastic astrocytoma patients were not statistically significantly different (893 +/- 157 vs. 728 +/- 61, respectively; P > 0.01).
  • A negative correlation between HGF and survival was found at five years of follow-up (R = -0.922, R (2) = 0.850, P < 0.001).
  • Also, the HGF concentration in CSF was a reliable means of explaining the highly variable survival of patients with malignant glioma.
  • Our findings support the idea that measurement of HGF in CSF could be a useful tool for monitoring the biological activity of malignant glioma.
  • [MeSH-minor] Adult. Analysis of Variance. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 2004 Jan;66(1-2):129-38 [15015778.001]
  • [Cites] Cancer Lett. 1998 Feb 27;124(2):149-55 [9500204.001]
  • [Cites] Int J Mol Med. 1999 May;3(5):531-6 [10202187.001]
  • [Cites] Zhonghua Yi Xue Za Zhi. 2005 Mar 30;85(12):835-8 [15949402.001]
  • [Cites] Neurosurgery. 1999 May;44(5):1077-82; discussion 1082-3 [10232541.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1721-9 [16452232.001]
  • [Cites] Cancer. 2002 Jun 15;94(12):3210-8 [12115353.001]
  • [Cites] J Neurooncol. 2006 Nov;80(2):143-9 [16648987.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9355-62 [16230398.001]
  • [Cites] Int J Cancer. 2006 May 1;118(9):2182-9 [16331629.001]
  • [Cites] Int J Dev Neurosci. 1999 Aug-Oct;17(5-6):517-30 [10571413.001]
  • [Cites] Int J Cancer. 2006 Feb 1;118(3):583-92 [16106403.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6144-52 [17062691.001]
  • [Cites] Front Biosci. 2004 Sep 01;9:3105-23 [15353341.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7443-8 [11416216.001]
  • [Cites] Cancer Res. 1997 Dec 1;57(23):5391-8 [9393765.001]
  • [Cites] Clin Cancer Res. 2005 Jun 15;11(12):4479-86 [15958633.001]
  • [Cites] J Natl Cancer Inst. 1999 Sep 15;91(18):1548-56 [10491431.001]
  • [Cites] Neuro Oncol. 2001 Apr;3(2):82-8 [11296484.001]
  • [Cites] Neuro Oncol. 2005 Oct;7(4):436-51 [16212809.001]
  • [Cites] Int J Cancer. 1999 Feb 19;84(1):10-8 [9988225.001]
  • [Cites] FASEB J. 2002 Jan;16(1):108-10 [11729097.001]
  • [Cites] Clin Cancer Res. 2003 Oct 1;9(12):4578-85 [14555533.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Jun 24;273(1):287-93 [10873600.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Jun 27;235(3):743-7 [9207232.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Aug 10;249(1):73-7 [9705834.001]
  • [Cites] Mol Cancer Res. 2008 Jan;6(1):139-50 [18234969.001]
  • [Cites] Clin Cancer Res. 2006 Feb 15;12(4):1292-8 [16489086.001]
  • (PMID = 19856144.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 67256-21-7 / Hepatocyte Growth Factor
  •  go-up   go-down


9. Wang Z, Wang W, Xu S, Wang S, Tu Y, Xiong Y, Mei J, Wang C: The role of MAPK signaling pathway in the Her-2-positive meningiomas. Oncol Rep; 2016 Aug;36(2):685-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of MAPK signaling pathway in the Her-2-positive meningiomas.
  • Meningiomas are common types of adult nerve system tumors.
  • Although most cases are considered benign, due to its high rate of recurrence and easy malignant progression to anaplastic meningioma they present a puzzle for the current treatment.
  • The HER-2 oncogene has important value for meningioma cells development and progression.
  • So far, little is known about the effect on the exact underlying signal pathway and molecular mechanisms of HER-2-positive meningioma cells.
  • The goal of the present study was to determine the effects of HER-2 gene and possible involvement of MAPK signal pathway in human malignant meningioma.
  • The results demonstrated that the downregulation of the expression of HER-2 significantly inhibited cell motility and proliferation of human meningioma cells in vivo.
  • Accordingly, in the HER-2-overexpression meningioma cells with the inhibition of ERK1/2, ERK5, JNK, in the cells with the ERK1/2, ERK5 inhibition, protein expression was markedly suppressed as well as the cell proliferation resistance.
  • No difference was observed in the HER-2-overexpression meningioma cells with the inhibition of JNK.
  • These findings suggest that HER-2 gene can affect the proliferation ability of human meningioma cells in vivo and MAPK signal pathway may contribute to the carcinogenesis and development of human meningiomas combinating with HER-2.


10. Gao F, Shi L, Russin J, Zeng L, Chang X, He S, Chen TC, Giannotta SL, Weisenberger DJ, Zada G, Mack WJ, Wang K: DNA methylation in the malignant transformation of meningiomas. PLoS One; 2013;8(1):e54114
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA methylation in the malignant transformation of meningiomas.
  • Meningiomas are central nervous system tumors that originate from the meningeal coverings of the brain and spinal cord.
  • Most meningiomas are pathologically benign or atypical, but 3-5% display malignant features.
  • Despite previous studies on benign and atypical meningiomas, the key molecular pathways involved in malignant transformation remain to be determined, as does the extent of epigenetic alteration in malignant meningiomas.
  • In this study, we explored the landscape of DNA methylation in ten benign, five atypical and four malignant meningiomas.
  • Compared to the benign tumors, the atypical and malignant meningiomas demonstrate increased global DNA hypomethylation.
  • Clustering analysis readily separates malignant from atypical and benign tumors, implicating that DNA methylation patterns may serve as diagnostic biomarkers for malignancy.
  • Genes with hypermethylated CpG islands in malignant meningiomas (such as HOXA6 and HOXA9) tend to coincide with the binding sites of polycomb repressive complexes (PRC) in early developmental stages.
  • Most genes with hypermethylated CpG islands at promoters are suppressed in malignant and benign meningiomas, suggesting the switching of gene silencing machinery from PRC binding to DNA methylation in malignant meningiomas.
  • One exception is the MAL2 gene that is highly expressed in benign group and silenced in malignant group, representing de novo gene silencing induced by DNA methylation.
  • In summary, our results suggest that malignant meningiomas have distinct DNA methylation patterns compared to their benign and atypical counterparts, and that the differentially methylated genes may serve as diagnostic biomarkers or candidate causal genes for malignant transformation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 2010 Sep;99(3):379-91 [20809251.001]
  • [Cites] Brain Pathol. 2010 Jul;20(4):751-62 [20015288.001]
  • [Cites] Nat Genet. 2011 Sep;43(9):825-7 [21804547.001]
  • [Cites] Nat Rev Cancer. 2011 Oct;11(10):726-34 [21941284.001]
  • [Cites] Genome Biol. 2011;12(8):R83 [21859476.001]
  • [Cites] Nat Genet. 2012 Jan;44(1):40-6 [22120008.001]
  • [Cites] Carcinogenesis. 2012 Feb;33(2):436-41 [22102699.001]
  • [Cites] Transl Res. 2012 Nov;160(5):355-62 [22735029.001]
  • [Cites] Brief Bioinform. 2013 Mar;14(2):178-92 [22517427.001]
  • [Cites] Cell. 1999 Oct 29;99(3):247-57 [10555141.001]
  • [Cites] Hum Mol Genet. 2000 Oct;9(16):2395-402 [11005794.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] Genes Dev. 2002 Jan 1;16(1):6-21 [11782440.001]
  • [Cites] Oncogene. 2003 May 29;22(22):3463-71 [12776198.001]
  • [Cites] CRC Crit Rev Biochem. 1982;13(4):349-84 [6185274.001]
  • [Cites] J Natl Cancer Inst. 1983 Oct;71(4):755-64 [6578371.001]
  • [Cites] Nucleic Acids Res. 1983 Oct 11;11(19):6883-94 [6314264.001]
  • [Cites] Cancer Res. 1987 Oct 15;47(20):5274-6 [2443238.001]
  • [Cites] Cancer Res. 1988 Mar 1;48(5):1159-61 [3342396.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Aug;85(15):5693-7 [2840671.001]
  • [Cites] Adv Cancer Res. 1990;54:1-23 [2404377.001]
  • [Cites] Cancer Cells. 1991 Oct;3(10):383-90 [1777359.001]
  • [Cites] Genomics. 1992 Aug;13(4):1095-107 [1505946.001]
  • [Cites] FEBS Lett. 1993 Apr 12;320(3):243-5 [8462693.001]
  • [Cites] Cancer Res. 1993 Jun 15;53(12):2715-8 [8389241.001]
  • [Cites] Cancer Res. 1993 Jun 15;53(12):2719-22 [8504410.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11995-9 [7505451.001]
  • [Cites] Nat Genet. 1998 Jul;19(3):219-20 [9662389.001]
  • [Cites] Cancer. 1999 May 1;85(9):2046-56 [10223247.001]
  • [Cites] Int J Cancer. 2005 Mar 20;114(2):249-56 [15540215.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):183-202 [15674477.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 [16199517.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):682-92 [16423997.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):729-35 [16424002.001]
  • [Cites] Nature. 2006 Feb 16;439(7078):871-4 [16357870.001]
  • [Cites] Methods Enzymol. 2006;411:134-93 [16939790.001]
  • [Cites] Lancet Neurol. 2006 Dec;5(12):1045-54 [17110285.001]
  • [Cites] Nat Genet. 2007 Feb;39(2):157-8 [17200673.001]
  • [Cites] Cell. 2007 Feb 23;128(4):683-92 [17320506.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):12979-84 [18753622.001]
  • [Cites] Cancer Res. 2010 Apr 1;70(7):2718-27 [20233874.001]
  • [Cites] Cell Res. 2011 Mar;21(3):502-17 [21321605.001]
  • (PMID = 23349797.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Databank-accession-numbers] GEO/ GSE42882
  • [Grant] United States / NCRR NIH HHS / RR / KL2 RR031991; United States / NCRR NIH HHS / RR / KL2RR031991
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Hoxa6 protein, human; 0 / Polycomb-Group Proteins; 0 / homeobox protein HOXA9
  • [Other-IDs] NLM/ PMC3551961
  •  go-up   go-down






Advertisement